Motor Evoked Potential and Cortical Silent Period in Migraine
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorIstanbul Gelisim University
About this trial
The primary objective of this study is to assess the level of inhibitory control in the motor cortex of migraine patients using objective and non-invasive methods. To this end, Motor Evoked Potential (MEP) and Cortical Silence Period (CSP) parameters obtained using Transcranial Magnetic Stimulation (TMS) will be measured and comparisons will be made between migraine patients and healthy controls. Since CSP duration is used specifically in the evaluation of GABA-B-mediated inhibitory mechanisms, it has the potential to directly measure the effect of migraine on cortical inhibition.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18-45 years.
Right-handed individuals.
Migraine patients: diagnosed according to International Headache Society (IHS) criteria.
Healthy controls: no history of migraine or other neurological disorders.
Disqualifiers
History of epilepsy or other seizure disorders.
Presence of metal implants, pacemakers, or other contraindications to TMS.
Pregnancy or breastfeeding.
History of significant neurological or psychiatric disorders.
Trial design
Design model
Parallel
Treatments tested in this trial
Transcranial Magnetic Stimulation (TMS)
Other interventionNon-invasive brain stimulation applied to the primary motor cortex to elicit motor evoked potentials (MEP) and cortical silent periods (CSP). 70 mm figure-of-eight coil used with Magstim 200² Monophasic Stimulator.
Surface Electromyography (sEMG)
DeviceBipolar Ag/AgCl electrodes placed over the first dorsal interosseous (FDI) muscle to record muscle responses to TMS.
Needle EMG / Single Motor Unit (SMU) Recording
Other interventionSterile Teflon-coated needle electrodes inserted into the FDI muscle to record activity of individual motor units during TMS and voluntary contractions.
Treatment groups
20 Participants
are divided into 2 treatment groupsGroup A: Migraine PatientsExperimental treatment 3 interventions
Group B: Healthy ControlsSham comparator 2 interventions
Trial outcomes
Primary outcomes
1
Cortical Silent Period (CSP) Duration
CSP duration will be recorded from the first dorsal interosseous (FDI) muscle using surface EMG during TMS. CSP reflects GABA-B-mediated cortical inhibitory mechanisms, allowing direct assessment of cortical inhibition in migraine patients compared to healthy controls.
Time frame
Single session measurement during TMSSecondary outcomes
1
Motor Evoked Potential (MEP) Amplitude
MEP amplitudes will be recorded from FDI muscle using surface EMG. Changes in MEP amplitude reflect cortical excitability and motor output.
Time frame
Single session measurement during TMSOther outcomes
1
Correlation Between Neurophysiological Parameters and Disease Duration
The relationship between TMS parameters (CSP duration, MEP amplitude) and the duration of the migraine disorder will be assessed using correlation analysis (Pearson or Spearman). Disease duration is determined based on the patient's medical history interview.
Time frame
Single session measurement during TMS2
Single Motor Unit (SMU) Firing Rate
The discharge rate (firing frequency) of single motor units recorded from the first dorsal interosseous (FDI) muscle using needle EMG during voluntary contraction.
Time frame
Single session measurement during TMSSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: